Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy.

Fang P, Boehling NS, Koay EJ, Bucheit AD, Jakob JA, Settle SH, Brown PD, Davies MA, Sulman EP.

J Neurooncol. 2018 Mar;137(1):67-75. doi: 10.1007/s11060-017-2695-2. Epub 2017 Dec 2.

PMID:
29198052
2.

Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations.

Bucheit AD, Chen G, Siroy A, Tetzlaff M, Broaddus R, Milton D, Fox P, Bassett R, Hwu P, Gershenwald JE, Lazar AJ, Davies MA.

Clin Cancer Res. 2014 Nov 1;20(21):5527-36. doi: 10.1158/1078-0432.CCR-14-1027. Epub 2014 Aug 27.

3.

Emerging insights into resistance to BRAF inhibitors in melanoma.

Bucheit AD, Davies MA.

Biochem Pharmacol. 2014 Feb 1;87(3):381-9. doi: 10.1016/j.bcp.2013.11.013. Epub 2013 Nov 28. Review.

PMID:
24291778
4.

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.

Bucheit AD, Syklawer E, Jakob JA, Bassett RL Jr, Curry JL, Gershenwald JE, Kim KB, Hwu P, Lazar AJ, Davies MA.

Cancer. 2013 Nov 1;119(21):3821-9. doi: 10.1002/cncr.28306. Epub 2013 Aug 6.

5.

An oncolytic measles virus engineered to enter cells through the CD20 antigen.

Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, Cattaneo RB, Fielding AK.

Mol Ther. 2003 Jan;7(1):62-72.

Supplemental Content

Loading ...
Support Center